Kirkland, Goodwin Guide Lilly's Potential $7B Kelonia Buy
Kirkland & Ellis LLP-advised pharmaceutical giant Eli Lilly & Co. on Monday announced plans to acquire clinical-stage biotechnology company Kelonia Therapeutics, led by Goodwin Procter LLP, in a deal worth up...To view the full article, register now.
Already a subscriber? Click here to view full article